Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Fig. 5

Landmark analysis of survival between patients with and without RCCEP. a Landmark survival analysis curve with 1.5 months as the cutoff time point. One hundred and ninety-five patients with PFS ≥ 1.5 months were included in the analysis. The RCCEP group consisted of patients with RCCEP within 1.5 months and the group without RCCEP consisted of patients without RCCEP within 1.5 months. b Landmark survival analysis curve with 3.0 months as the cutoff time point. One hundred and ninety patients with OS ≥ 3.0 months were included in the analysis. The RCCEP group consisted of patients with RCCEP within 3.0 months, and the group without RCCEP consisted of patients without RCCEP within 3.0 months. c Landmark survival analysis curve with 5.0 months as the cutoff time point. One hundred and sixty-nine patients with OS ≥ 5.0 months were included in the analysis. The RCCEP group consisted of patients with RCCEP within 5.0 months, and the group without RCCEP consisted of patients without RCCEP within 5.0 months. RCCEP, reactive cutaneous capillary endothelial proliferation; PFS, progression-free survival; OS, overall survival

Back to article page